SLC5A2 and type 2 diabetes mellitus: In large-scale clinical studies such as EMPA-REG OUTCOME, the consistent and significant benefits of different SGLT2 inhibitors for T2DM patients carrying a high CV risk suggest the potential therapeutic value of these agents for HFpEF.